Henn Matthew R sold $369 of MCRB
Henn Matthew R (See Remarks) sold 81 shares of Seres Therapeutics, Inc. (MCRB) at $4.55 on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale of 81 shares at $4.55 by an officer under a 10b5-1 plan, reducing direct holdings to 7,995 shares.
Market read
This is a routine, small insider sale disclosure with limited expected impact on trading decisions absent other catalysts.
What to watch
The article provides only the sale details, not any concurrent operational or clinical catalysts, so the signal should be weighted lightly versus fundamental news.
Background
The article is a SEC Form 4 insider transaction disclosure for Seres Therapeutics, Inc. (MCRB).
Ticker impact
Seres Therapeutics insider Henn Matthew R sold 81 shares at $4.55 under a 10b5-1 plan, disclosing direct ownership reduction.
Likely minimal immediate price impact; any effect would be sentiment-only and small.
The filing is a Form 4 open-market sale with a stated 10b5-1 plan, and the disclosed size ($368.55) is small relative to typical market-moving thresholds.
Market effects
No clear sector read-through from a small, planned insider sale.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with private views; traders may still watch for follow-on insider activity or changes in trading patterns.
Key entities
- issuerSeres Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderHenn Matthew R
Officer who executed the open-market sale under a 10b5-1 plan.
